In a show of commitment to Innate Pharma SA’s antibody-based natural killer cell engager therapeutics (Anket) platform, longstanding partner Sanofi SA is paying €25 million (US$26.5 million) up front and could pay up to €1.35 billion more in preclinical, clinical, regulatory, and commercial milestones for up to three development programs. Innate also stands to receive royalties on eventual product sales.
Sosei Heptares and Eli Lilly and Co. have signed a potential $731 million deal to discover, develop and commercialize small molecules that modulate G protein-coupled receptor (GPCR) targets associated with diabetes and metabolic diseases.
Innovent Biologics Inc. has in-licensed LG Chem Ltd.’s tigulixostat (LC-350189), a late-stage non-purine xanthine oxidase inhibitor (XOI) for managing chronic hyperuricemia in patients with gout, in a deal worth up to $95 million.
Transition ultrasound startup QT Imaging Inc. is poised to go public via a merger with Gigcapital5 Inc., a special purpose acquisition company (SPAC), in a deal that puts the equity value of the combination at $151 million. The combined company, QT Imaging Holdings Inc. will be traded on the NYSE under the ticker symbol QTI.
Pediatrix Therapeutics Inc. licensed exclusive China rights to Aclaris Therapeutics Inc.'s ATI-1777 for investigational “soft” JAK 1/3 inhibitor, for diseases including atopic dermatitis, in exchange for an up-front payment of $5 million and up to $91 million in milestones.
Tandem Diabetes Care Inc. entered a definitive agreement to acquire AMF Medical SA for CHF 62.4 million (US$67.1 million) in cash at closing plus future payments of as much as CHF 129.6 million (US$139.43 million) contingent on meeting certain milestones. Tandem also invested CHF 8 million (US$8.6 million) in AMF in the third quarter of 2022. The transaction is expected to close in January 2023.
While biopharma deal values were down year-over-year in November by 7.6%, that gap has now doubled, showing a 15.5% decline in values in 2022. There has been a significant slowdown in activity in the second half of the year. Values were up by 7% in early August 2022. All told, 1,422 deals, including licensings, joint ventures and collaborations, have brought the industry a potential $169.2 billion through the first week of December.
Wave Life Sciences Ltd. is partnering again. The company is getting $170 million up front – $120 million in cash and a $50 million equity investment – in a new partnership with GSK plc to advance oligonucleotides in unnamed targets. The agreement, which has a four-year research term, allows for GSK to advance up to eight programs using Wave Life’s platform and for Wave Life to advance three, or more if GSK approves, of its own collaboration programs.
Sotyktu (deucravacitinib), the tyrosine kinase 2 (TYK2) inhibitor for psoriasis from Bristol Myers Squibb Co., is “a good first-in-class” drug, said Nimbus Therapeutics LLC CEO Jeb Keiper, but his firm may have the best in class, ready for phase III trials. Takeda Pharmaceutical Co. Ltd. apparently believes so. The company has agreed to pay $4 billion up front and pledge as much as $2 billion more in potential milestone payments to acquire Nimbus’s wholly owned subsidiary, Nimbus Lakshmi Inc., thereby bringing aboard the TYK2 prospect called NDI-034858.
Less than a month from its launch as a stand-alone business on Jan. 4, 2023, GE Healthcare Holding LLC provided a glimpse of its future plans for growth and anticipated financials for investors. The soon-to-be-launched company is hardly waiting until its spinoff to look for tuck-in acquisitions to boost sales and profitability and add new capabilities for customers and patients.
RSS
